On Monday, Lupin announced that it has got a tentative approval from the US health regulator to offer Dasatinib tablets, which are used to treat specific forms of cancer, in the US.
Dasatinib tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg have been approved by the US Food and Drug Administration (FDA), the company in partnership with Pharmascience Inc. stated in a statement.
The medicine produced by the Mumbai-based company is a generic version of the Sprycel tablets sold by Bristol-Myers Squibb Company.
Dasatinib tablets had an estimated annual sale of USD 1,569 million in the US, according to IQVIA MAT data.
On the BSE, shares of Lupin closed at Rs 662.50 each, up 1.49 percent.